1. A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Issue 2 (1st February 2023) Authors: Palomba, M Lia; Ghione, Paola; Patel, Anik R; Nahas, Myrna; Beygi, Sara; Hatswell, Anthony J; Kanters, Steve; Limbrick-Oldfield, Eve H.; Wade, Sally W; Ray, Markqayne D; Owen, Jessica; Neelapu, Sattva S; Gribben, John; Radford, John; Bobillo, Sabela Journal: Expert review of anticancer therapy Issue: Volume 23:Issue 2(2023) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B‐cell lymphoma. (23rd August 2013) Authors: Coiffier, Bertrand; Radford, John; Bosly, André; Martinelli, Giovanni; Barca, Gabriela; Davies, Andrew; Decaudin, Didier; Gallop‐Evans, Eve; Padmanabhan‐Iyer, Swaminathan; Van, Koen; Wu, Ka Lung; Gupta, Ira V.; Lin, Thomas S.; Goldstein, Nancy; Jewell, Roxanne C.; Winter, Paul; Lisby, Steen Journal: British journal of haematology Issue: Volume 163:Number 3(2013:Nov.) Page Start: 334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Issue 10 (3rd October 2015) Authors: Wagner-Johnston, Nina D.; Goy, Andrè; Rodriguez, Maria A.; Ehmann, W. Christopher; Hamlin, Paul A.; Radford, John; Thieblemont, Catherine; Suh, Cheolwon; Sweetenham, John; Huang, Yifan; Sullivan, Sharon T.; Vandendries, Erik R.; Gisselbrecht, Christian Journal: Leukemia & lymphoma Issue: Volume 56:Issue 10(2015:Oct.) Page Start: 2863 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma. (26th February 2015) Authors: Collins, Graham P.; Eyre, Toby A.; Linton, Kim M.; Radford, John; Vallance, Grant D.; Soilleux, Elizabeth; Hatton, Chris Journal: British journal of haematology Issue: Volume 170:Number 6(2015:Sep.) Page Start: 886 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. A Randomized Study of Interferon α‐2b Versus No Treatment as Consolidation After High Dose Therapy and Autologous Stem Cell Transplantation for Patients With Relapsed Lymphoma. (8th October 2013) Authors: Bosly, André; Grigg, Andrew; Holte, Harald; Gisselbrecht, Christian; Radford, John; Rossi, Andrea; Lopez‐Guillermo, Armando; Trneny, Marek; Sebban, Catherine; Hagberg, Hans; Leal da Costa, Fernando; Colombat, Philippe; Bron, Dominique; Coiffier, Bertrand Journal: Oncologist Issue: Volume 18:Number 11(2013) Page Start: 1189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin. (22nd July 2016) Authors: Howell, Matthew; Gibb, Adam; Radford, John; Linton, Kim Journal: British journal of haematology Issue: Volume 179:Number 5(2017) Page Start: 841 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced‐stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high‐risk patients from the ECHELON‐1 study. Issue 2 (16th February 2021) Authors: Hutchings, Martin; Radford, John; Ansell, Stephen M.; Illés, Árpád; Sureda, Anna; Connors, Joseph M.; Sýkorová, Alice; Shibayama, Hirohiko; Abramson, Jeremy S.; Chua, Neil S.; Friedberg, Jonathan W.; Kořen, Jan; LaCasce, Ann Steward; Molina, Lysiane; Engley, Gerald; Fenton, Keenan; Jolin, Hina; L... Journal: Hematological oncology Issue: Volume 39:Issue 2(2021) Page Start: 185 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial. Issue 6 (June 2021) Authors: Straus, David J; Długosz-Danecka, Monika; Connors, Joseph M; Alekseev, Sergey; Illés, Árpád; Picardi, Marco; Lech-Maranda, Ewa; Feldman, Tatyana; Smolewski, Piotr; Savage, Kerry J; Bartlett, Nancy L; Walewski, Jan; Ramchandren, Radhakrishnan; Zinzani, Pier Luigi; Hutchings, Martin; Munoz, Javier;... Journal: Lancet Issue: Volume 8:Issue 6(2021) Page Start: e410 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Issue 6 (June 2021) Authors: Hamadani, Mehdi; Collins, Graham P; Caimi, Paolo F; Samaniego, Felipe; Spira, Alexander; Davies, Andrew; Radford, John; Menne, Tobias; Karnad, Anand; Zain, Jasmine M; Fields, Paul; Havenith, Karin; Cruz, Hans G; He, Shui; Boni, Joseph; Feingold, Jay; Wuerthner, Jens; Horwitz, Steven Journal: Lancet Issue: Volume 8:Issue 6(2021) Page Start: e433 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial. Issue 5 (May 2018) Authors: Gleeson, Mary; Peckitt, Clare; To, Ye Mong; Edwards, Laurice; Oates, Jacqueline; Wotherspoon, Andrew; Attygalle, Ayoma D; Zerizer, Imene; Sharma, Bhupinder; Chua, Sue; Begum, Ruwaida; Chau, Ian; Johnson, Peter; Ardeshna, Kirit M; Hawkes, Eliza A; Macheta, Marian P; Collins, Graham P; Radford, Joh... Journal: Lancet Issue: Volume 5:Issue 5(2018) Page Start: e190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗